Mirvetuximab soravtansine (ImmunoGen) is a folate receptor alpha (FRa)-targeted antibody-drug conjugate (ADC) in development for advanced ovarian cancer patients that overexpress FRa. It is comprised of an FRa-targeted monoclonal antibody linked to the cytotoxic effector compound maytansinoid DM4. As an ADC, the FRa-targeted antibody ensures tumor-directed delivery of maytansinoid DM4, which induces mitotic arrest by suppressing microtubule dynamics. Folate receptors have limited distribution in normal tissues, but FRa overexpression is characteristic of several tumor types including ovarian, breast, brain, lung, and colorectal cancer. FRa is overexpressed in approximately 70% of primary ovarian tumors and over 80% of recurrent tumors.
As the only drug directly targeting the FRa-positive (FRa+) patient population, mirvetuximab soravtansine could become a standard choice in this setting. Early-phase data indicate the drug is active and tolerable in FRa+ platinum-resistant ovarian cancer patients as a monotherapy. The Phase III FORWARD I trial has been initiated to confirm these results and will better determine the drug’s place in the ovarian cancer treatment paradigm.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 mirvetuximab soravtansine : Ovarian cancer
LIST OF FIGURES
9 Figure 1: Mirvetuximab soravtansine for ovarian cancer – SWOT analysis
10 Figure 2: Datamonitor Healthcare’s drug assessment of mirvetuximab soravtansine for ovarian cancer
11 Figure 3: Datamonitor Healthcare’s drug assessment of mirvetuximab soravtansine for ovarian cancer
LIST OF TABLES
5 Table 1: Mirvetuximab soravtansine drug profile
6 Table 2: Mirvetuximab soravtansine Phase III trial in ovarian cancer
8 Table 3: Phase I data for mirvetuximab soravtansine in ovarian cancer
9 Table 4: Ongoing Phase Ib/II trial of mirvetuximab soravtansine in ovarian cancer
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.